CRNX
NASDAQ · Pharmaceuticals
Crinetics Pharmaceuticals In
$37.48
-6.01 (-13.82%)
Financial Highlights (FY 2026)
Revenue
8.56M
Net Income
-517,998,239
Gross Margin
86.0%
Profit Margin
-6,046.2%
Rev Growth
+17.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 86.0% | 86.0% | 49.0% | 49.0% |
| Operating Margin | -6,714.8% | -6,043.3% | 33.0% | 33.9% |
| Profit Margin | -6,046.2% | -5,743.9% | 30.3% | 28.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 8.56M | 7.29M | 1.14B | 877.84M |
| Gross Profit | 7.37M | 6.27M | 560.24M | 429.81M |
| Operating Income | -575,113,067 | -440,399,693 | 378.01M | 297.31M |
| Net Income | -517,998,239 | -396,663,332 | 346.78M | 252.83M |
| Gross Margin | 86.0% | 86.0% | 49.0% | 49.0% |
| Operating Margin | -6,714.8% | -6,043.3% | 33.0% | 33.9% |
| Profit Margin | -6,046.2% | -5,743.9% | 30.3% | 28.8% |
| Rev Growth | +17.5% | +17.5% | +24.5% | +7.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 968.32M | 1.13B |
| Total Equity | — | — | 3.49B | 3.49B |
| D/E Ratio | — | — | 0.28 | 0.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -571,335,137 | -461,812,626 | 475.78M | 336.75M |
| Free Cash Flow | — | — | 205.84M | 188.22M |